Heart Failure Drug Shows Promise

Monday, 31 Mar 2014 12:34 PM


  Comment  |
   Contact  |
  Print   |
    A   A  
  Copy Shortlink
Novartis has ended a late-stage clinical trial of a chronic heart failure drug early, following strong interim results, giving the Swiss drugmaker a boost after recent setbacks to another heart failure medicine.
The Basel-based firm said on Monday an independent committee had unanimously recommended it close its PARADIGM-HF study ahead of time after results showed patients receiving its LCZ696 drug lived longer without being hospitalized for heart failure than those who were given enalapril, the standard care.
The Swiss drugmaker, long a major player in cardiovascular medicine, is looking to LCZ696 as one of two new treatments for heart failure that could revive its fortunes as top-selling blood pressure pill Diovan faces generic competition.
Novartis said it would present the full data at an upcoming conference and seek approval for the drug from global regulators.
"If full results are robust, LCZ696 could represent another blockbuster drug in the category of cardiovascular medicine that the company knows well," Bernstein analyst Tim Anderson said, adding he was aware of no near-term competitors for the drug.
Citi analyst Andrew Baum said the drug could have the potential to achieve peak annual sales of more than $5 billion and could become the first new medicine to be approved for chronic heart failure in over a decade.
At 0840 GMT, shares in Novartis were up 1.9 percent at 74.35 Swiss francs, outperforming a 0.5 percent firmer European healthcare sector index.
The positive news for LCZ696 contrasts with recent setbacks for Novartis' other acute heart failure drug, Serelaxin.
Last week, a panel of advisers to the U.S. Food and Drug Administration recommended Serelaxin not be approved because of insufficient evidence it improves symptoms, echoing a recommendation by European regulators which also ruled against the drug.
Heart failure is a condition where the heart struggles to pump blood around the body. Unlike a heart attack, in which a heart artery becomes blocked, it develops progressively.
More than 20 million people suffer from heart failure in Europe and the United States alone, Novartis said.
LCZ696, a twice a day pill, is a combination of Diovan, or valsartan, and another class of drug called a neprilysin inhibitor.
The study was evaluating LCZ696 in patients with so-called reduced ejection fraction chronic heart failure.

© 2014 Thomson/Reuters. All rights reserved.

  Comment  |
   Contact  |
  Print   |
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
Zip Code:
Privacy: We never share your email.
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Migraines Raise Risk of Bell's Palsy

Wednesday, 17 Dec 2014 17:26 PM

People who suffer from migraine headaches have double the risk of developing Bell's palsy, a condition that causes facia . . .

Pilots Exposed to Tanning Bed Radiation Levels: Study

Wednesday, 17 Dec 2014 17:01 PM

Airline pilots get as much exposure to cancer-causing UV rays in an hour-long flight as they would during 20 minutes in  . . .

How Exercise Changes Our DNA

Wednesday, 17 Dec 2014 14:39 PM

If you exercise regularly hoping to improve your health, you may wonder exactly how your huffing and puffing translates  . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

America's News Page
©  Newsmax Media, Inc.
All Rights Reserved